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Abstract
Background Pazopanib is a standard treatment for meta-
static renal cell carcinoma (mRCC), and 800 mg/daily is
considered the optimal dose. However, some patients
require dose modification because of toxicity. Whether a
reduced dose of pazopanib is as effective as the standard
dose in achieving clinical benefit remains unclear.
Objectives Our objective was to conduct a retrospective
analysis to investigate the clinical effect of different ther-
apeutic doses of first-line pazopanib in patients with
mRCC.
Methods Consecutive patients with mRCC treated with
first-line pazopanib between 2011 and 2016 at the Istituto
Nazionale Tumori of Milan were retrospectively analysed
for demographics, response, outcomes, and toxicity. Three
patient groups were compared: group 1 received the stan-
dard dose of 800 mg/day; group 2 started with 800 mg/day
and then reduced the dose to 400 or 600 mg/day because of
toxicity; and group 3 received a reduced starting dose of
400 or 600 mg/day because they had an Eastern Cooper-
ative Oncology Group (ECOG) performance status (PS) of
2 and/or comorbidities.
Results In total, 69 patients were evaluated: 34 in group
1, 19 in group 2, and 16 in group 3. After a median
follow-up of 13.9 months (range 0.3–43.8), 27 (39.1%)
patients had progressive disease (PD) and three (4.3%)
patients had died. The incidence rate of PD or death per
100 person-months was 2.5 [95% confidence interval (CI)
0.6–4.4; hazard ratio (HR) 1] in group 1 and 3.9 (95% CI
0–14.3; HR 1.43) in the combined group (2 ? 3). The
discontinuation rate due to PD was 28% in group 1, 42%
in group 2, and 44% in group 3. The objective response
rate was 44, 11, and 19% in groups 1, 2, and 3,
respectively.
Conclusions Our results may suggest that patients with
mRCC receiving a lower dose of first-line pazopanib
might not have a meaningful progression-free survival
advantage compared with those receiving a standard dose.
These data highlight that proper management of treat-
ment-related side effects may lead to optimal drug
exposure.
Key Points
Patients receiving first-line pazopanib for metastatic
renal cell carcinoma (mRCC) often undergo dose
modifications because of comorbidities or toxicity,
but whether reduced-dose pazopanib is as effective
as the standard dose in achieving a clinical benefit is
unclear.
This study may suggest that patients with mRCC
who receive a lower dose of first-line pazopanib
might not have a meaningful progression-free
survival advantage compared with those receiving a
standard dose.
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1 Introduction
Agents that target angiogenesis through the vascular
endothelial growth factor (VEGF) pathway are the back-
bone of therapy for metastatic renal cell carcinoma
(mRCC) [1, 2]. Variations in drug levels in patients treated
with VEGF receptor (VEGFR) tyrosine kinase inhibitors
(TKIs) represent a significant challenge in the treatment of
patients with mRCC. Plasma exposure varies according to
dose, and correlation is lacking between plasma levels and
efficacy in individual patients [3, 4]. The pharmacokinetics
of TKIs have demonstrated significant interindividual
variability, which might contribute to the variable clinical
response observed in patients receiving these drugs [5]. As
a result, the variability in plasma exposure and clinical
efficacy is reflected in the dosing recommendations for
these TKIs. In addition, a number of factors affect the
efficacy of a drug or treatment regimen in patients with
cancer, including patient and tumor characteristics, tumor
biology, and systemic exposure to the drug, which may
vary because of schedule and/or dosing modifications due
to toxicity [6]. Whether current dosing and schedules for
TKIs are optimal in terms of achieving a maximum ther-
apeutic response remains unclear, and a subset of patients
will continue to have subtherapeutic drug levels such that
progressive disease (PD) during VEGFR TKI therapy
might not be a product of resistance to therapy but rather a
result of underdosing. First-line pazopanib is one of the
standard options for treatment-naı¨ve mRCC [2], but it is
frequently associated with adverse events (AEs) and dose
reductions. The most common AEs related to pazopanib
include fatigue, nausea, diarrhea, hypertension, anorexia,
and hair depigmentation, as well as aspartate transaminase
(AST) and alanine transaminase (ALT) elevations [2].
Liver abnormalities (3.8%), diarrhea (2%), and arterial
thrombotic events (2%) are the most common reasons for
treatment discontinuation. Toxicity often leads to dose
reductions or treatment discontinuation, which might
improve tolerability; however, whether a reduced dose is
comparable to a standard dose in achieving response or
delaying disease progression is unclear. The goal of the
present retrospective analysis was to investigate the clinical
effect of different therapeutic doses of first-line pazopanib
in patients with mRCC.
2 Materials and Methods
2.1 Patients and Treatment
This was a single-center retrospective cohort study. Details
of consecutive patients with mRCC treated with pazopanib
as a first-line targeted therapy between 2011 and 2016 at
the Istituto Nazionale Tumori of Milano (Italy), a com-
prehensive cancer center, were analyzed. Baseline demo-
graphics, including comorbidities and treatment duration,
were evaluated. After reviewing the therapeutic schedule
and dosage, investigators divided patients into three
groups: patients who started treatment with the standard
oral pazopanib 800 mg daily and continued to receive the
same dose throughout the treatment (group 1); patients who
switched from oral pazopanib 800 mg daily to oral pazo-
panib 600 or 400 mg daily because of intolerable toxicity
or patient refusal to continue treatment at the same dose
(group 2); and frail subjects who started treatment with oral
pazopanib 400 mg or 600 mg daily because of a low
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) of 2 or comorbidities according to local
treating clinical practice (group 3).
2.2 Data Analysis
The primary study outcome was progression-free survival
(PFS), defined as the time from initiation of pazopanib
therapy to the date of first documented disease progression,
loss to follow-up, or death due to any cause, whichever
occurred first. Secondary study outcomes included treat-
ment duration, discontinuation rate, and treatment
response. Treatment response was assessed using the
RECIST (Response Evaluation Criteria in Solid Tumors)
version 1.1 criteria [7], whereas requirements for dose
reduction and assessment of toxicity were evaluated
according to CTCAE (Common Terminology Criteria for
Adverse Events) version 4.0 [8].
2.3 Statistical Analyses
The PFS incidence rate was calculated as the ratio between
the number of PFS events and the sum of total PFS time
contributed by all patients. Because of the treatment shift to
a reduced dose from group 1 to group 2, survival functions
were estimated using the Simon–Makuch method. The Cox
regression model was used to detect the statistical associ-
ation and to estimate the hazard ratio (HR). Median follow-
up time was estimated using the reverse Kaplan–Meier
method. The objective response rate (ORR) was calculated
as the percentage of complete and partial treatment
response. Baseline covariate distributions and treatment
characteristics were summarized using descriptive statistics
(median and range for continuous variables; absolute and
percentage frequencies for categorical variables). All sta-
tistical tests were two-sided. Given the descriptive nature
of the study, hypothesis testing was applied qualitatively
(i.e., no threshold for statistical significance was defined).
Statistical analysis was performed using SAS version 9.2
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(SAS Institute Inc., Cary, NC, USA). The Kaplan–Meier
curves were plotted using STATA software version 12.1
(StataCorp, College Station, TX, USA).
3 Results
From June 2011 to September 2016, a total of 69 patients
started treatment with first-line pazopanib; 34 (49%), 19
(28%), and 16 subjects (23%) were evaluated in groups 1,
2, and 3, respectively. The median age at diagnosis was
62 years, and 64% were male. Overall, 13% and 87% of
patients were classified as Heng ‘good’ and ‘intermediate’
risk, respectively. Patients’ baseline characteristics are
reported in Table 1. Cardiovascular comorbidities at
baseline were observed in ten (29%), six (32%), and 14
(88%) patients in groups 1, 2, and 3, respectively (Table 1).
3.1 Treatment and Adverse Event Profile
After starting oral pazopanib treatment at the full dose
(800 mg daily), 16 patients (84%) reduced the dose to
400 mg daily, and three (16%) reduced the dose to 600 mg
daily (overall, 19 patients who were defined as group 2).
The most frequent reasons for reducing the dose were
grade 2 fatigue (n = 2; 11%), mucositis (n = 1; 5%),
diarrhea (n = 1; 5%), nausea (n = 3; 16%), neutropenia
(n = 1; 5%), mucositis (n = 1; 5%), hypertransami-
nasemia (n = 3; 16%), and hypertension (n = 3; 16%) and
grade 3 hypertension (n = 7; 37%), hypertransaminasemia
(n = 4; 21%), and fatigue (n = 8; 42%). In total, 34 (56%)
patients who started on pazopanib 800 mg daily main-
tained the full dose of pazopanib. The most frequent tox-
icities reported among these patients were grade 1 diarrhea
(n = 5; 33%), fatigue (n = 7; 47%), hypertension (n = 1;
7%), mucositis (n = 1; 7%), and skin rash (n = 1; 7%) and
grade 2 diarrhea (n = 2; 13%), nausea (n = 1; 7%),
vomiting (n = 1; 7%), fatigue (n = 2; 13%), and hyper-
tension (n = 1; 7%). In group 3, a total of 12 (75%) sub-
jects started treatment at a reduced dose of 400 mg daily,
and four (25%) started at 600 mg daily. The most frequent
reason for starting treatment at a reduced dose was car-
diovascular comorbidity, including uncontrolled hyperten-
sion in seven patients (44%), previous acute myocardial
infarction in three patients (19%), previous transient
ischemic attack in two patients (12.5%), arrhythmias in
three patients (19%), and Felty’s syndrome in one case, and
three of these patients presented with an ECOG PS of 2
(Table 1). The incidence of some grade 3 toxicities com-
monly associated with pazopanib were fatigue (20% in
group 1 vs. 6% in group 2 ? 3), hypertension (13% in
group 1 vs. 0% in group 2 ? 3), and liver function test
failure (6% in group 1 vs. 0% in group 2 ? 3) (Table 2).
3.2 Treatment Duration and Survival
After a median follow-up of 13.9 months (range 0.3–43.8),
27 (39.1%) patients had PD and three (4%) patients had
died (total PFS events 30). At the date of last follow-up, 17
(50%), seven (37%), and six (38%) patients were alive and
receiving treatment in groups 1, 2, and 3, respectively,
whereas 17 (50%), 12 (63%), and ten (62%) patients had
discontinued treatment because of PD or toxicity or were
lost to follow-up. Patients had been taking pazopanib for a
median of 9.6 months (range 0.3–43.8) in group 1, for
13.6 months (range 0.1–29.5) in group 2, and for
18.3 months in group 3. The PFS incidence rate per 100
person-months was 2.5 [95% confidence interval (CI)
0.6–4.4; HR 1] in group 1 and 3.9 [95% CI 0.68–2.98; HR
1.43 (95% CI 0.68–2.98)] in group 2 ? 3 (Table 3). Rates
of discontinuation due to PD were 28% (15 patients) in
group 1, 42% (eight patients) in group 2, and 44% (seven
patients) in group 3. The ORR was 44, 11, and 19% in
groups 1, 2, and 3, respectively. When dose-reduction
groups 2 and 3 were considered together and defined as a
group (2 ? 3), the PFS incidence rates were as summa-
rized in Table 3. Median PFS was not reached in group 1
and was 17.9 months (95% CI 7.6–44.8) for group 2 ? 3
(Figs. 1, 2). Before a PFS event, patients had been taking
pazopanib for a median of 9.6 months (range 0.3–43.8) in
group 1, for 13.6 months (range 0.1–29.5) in group 2, and
for 18.3 months (range 2.1–31.4) in group 3. At the uni-
variate analysis, the dose-reduction group (2 ? 3) was
associated with less favorable survival (HR 1.43; 95% CI
0.68–2.98; p = 0.343) than was group 1. The multivariate
analysis confirmed that the worse outcome was associated
with dose reduction (HR 1.44; 95% CI 0.69–3.00) for the
dose-reduction group (2 ? 3), whereas the Heng prog-
nostic score discriminated between a ‘good’ and an ‘in-
termediate’ score (HR 0.66; 95% CI 0.20–2.17; p = 0.501)
in the overall population analysed. In group 1, three
patients experienced complete response (CR), 12 patients
experienced partial response (PR), and 11 patients experi-
enced stable disease (SD), with an ORR (CR ? PR) of
44%. In group 2, no CRs were reported, whereas two and
seven patients achieved PR and SD, respectively, with an
ORR of 11%. In group 3, no CRs were seen, whereas three
patients reported a PR and four patients reported SD, with
an ORR of 19 (Table 4).
4 Discussion
Pazopanib is a recommended first-line option for the
treatment of mRCC [9, 10]. Retrospective data have shown
that an increased median PFS and tumor shrinkage appear
in patients with higher plasma trough drug levels (Cmin)
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[11]. Therefore, patients with a low Cmin might benefit
from pharmacokinetically guided individualized dosing.
Dose reductions to pazopanib 400 mg occurred in 30% of
patients with RCC in the phase II study [12]. The most
common AEs leading to dose interruptions or reductions
were diarrhea, hypertension, and increased ALT/AST
levels [12]. Results suggest that the frequency of these
common AEs could be reduced by decreasing systemic
exposure to pazopanib through dose reductions or inter-
ruptions. However, interpatient heterogeneity in the meta-
bolism and/or absorption of pazopanib can lead to
differences in systemic exposure. Nevertheless, in clinical
practice, both comorbidities and AEs might limit the
pazopanib dosage and affect therapeutic response. To
investigate the greatest benefit, we analyzed the relation-
ship between different pazopanib doses and efficacy. In our
Table 1 Patient characteristics
Characteristic Full dose (N = 34) Dose reduction (N = 19) Starting dose reduction (N = 16) Total patients (N = 69)
Sex
Male 27 (79) 6 (32) 10 (63) 43 (62)
Female 7 (21) 13 (68) 6 (37) 26 (38)
Median age (years)
62
ECOG performance status
0 27 (79) 18 (95) 6 (38) 51 (74)
1 6 (18) 1 (5) 7 (44) 14 (20)
2 1 (3) – 3 (19) 4 (6)
Comorbidities
Cardiovascular 10 (29) 6 (32) 14 (88) 30 (43)
Diabetes mellitus 4 (12) 2 (11) 4 (25) 10 (14)
Other 2 (6) 2 (11) 2 (13) 6 (9)
Histology
Clear cell 34 (100) 19 (100) 15 (94) 68 (99)
Non-clear cell – – 1 (6) 1 (1)
Nephrectomy
Yes 32 (94) 19 (100) 16 (100) 67 (97)
No 2 (6) – – 2 (3)
Heng score
Good 6 (18) 2 (811) 2 (13) 10 (14)
Intermediate 27 (79) 17 (89) 14 (88) 58 (84)
Poor 1 (3) – – 1 (1)
Metastatic sites (N)
1 14 (41) 8 (44a) 7 (44) 29 (42)
2 19 (56) 7 (39a) 6 (38) 32 (46)
3–6 2 (6) 3 (17a) 3 (19) 8 (12)
Metastatic sites
Lymph node 14 (41) 2 (11a) 6 (38) 22 (32)
Bone 9 (26) 3 (17a) 2 (13) 14 (20)
Lung 3 (9) 7 (39a) 2 (13) 12 (17)
Pancreas 3 (9) 7 (39a) 2 (13) 12 (17)
Contralateral kidney 1 (3) 2 (11a) 2 (13) 5 (7)
Liver 2 (6) 3 (17a) 2 (13) 7 (10)
Otherb 7 (21) 1 (5) 3 (19) 11 (16)
Data are presented as N (%) unless otherwise indicated
ECOG Eastern Cooperative Oncology Group, PS performance status
a Sites of disease missing for one patient
b Pleura, brain, skin, adrenal gland
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study, the majority of patients started on the standard dose
of pazopanib 800 mg daily; however, 19 (36%) of these
patients required a dose reduction, and 16 (23%) patients
started pazopanib on a reduced dose because of comor-
bidities. On the other hand, 14 (41%), nine (47.4%), and
nine (56.3%) patients in groups 1, 2, and 3, respectively,
discontinued treatment because of PD or toxicity. The most
common AEs observed in our study were fatigue (33.3%),
nausea (17.4%), diarrhea (16%), and hypertension (13%),
which is consistent with data in the literature [2]. Treat-
ment duration and toxicity data from real-world experience
with sunitinib and sorafenib show that, overall, about half
of patients require a dose reduction of sunitinib [13] and
sorafenib [14, 15] because of toxicity; however, no similar
Table 2 Pazopanib administration and adverse events profile
Characteristics Group 1 Group 2 Group 3 Total
Pazopanib starting dose (mg/daily)
800 53 (77) 19 (36) – 53 (77)
600 – – 4 (25) 4 (6)
400 – – 12 (75) 12 (17)
Dose reduction (mg/daily)
Yes 19 (36) 19 (36) 16 (23) 35 (51)
600 3 (6) – 3 (4)
400 16 (30) –
No 34 (64) – – 34 (49)
Fatigue
Grade 1 and 2 9 (27) 2 (11) 9 (56) 20 (29)
Grade 3 1 (3) 1 (5) 1 (6) 3 (4)
Hypertension
Grade 1 and 2 4 (8) 3 (16) 2 (12) 9 (13)
Grade 3 2 – – 2 (3)
Mucositis
Grade 1 and 2 1 (3) 1 (5) – 2 (3)
Grade 3 – – – –
Diarrhea
Grade 1 and 2 7 (21) 2 (11) – 9 (13)
Grade 3 – 3 (16) – 3 (4)
Nausea
Grade 1 and 2 1 (3) 3 (16) 7 (44) 11 (16)
Grade 3 1 (3) – – 1 (1)
Liver toxicity
Grade 1 and 2 1 (3) 3 (16) 2 (12) 6 (9)
Grade 3 1 (3) – – 1 (1)
Skin rash
Grade 1 and 2 1 (3) – – 1 (1)
Grade 3 – – – –
Data are presented as point estimate (95% confidence interval) unless otherwise indicated
NA not applicable
a Incidence rate is presented as events per 100 person-months
Table 3 Progression-free survival incidence rate and hazard ratio for
groups 1 and (2 ? 3)
Group Incidence ratea Hazard ratio p value
1 2.5 (0.6–4.4) 1 (NA) 0.343
(2 ? 3) 3.9 (0–14.3) 1.43 (0.68–2.98)
Multivariate analysis
Group
1 1 (NA) 0.334
(2 ? 3) 1.44 (0.69–3.00)
Heng score
Poor–intermediate 1 (NA) 0.488
Good 0.66 (0.20–2.17)
Data are presented as n (%)
Dose Modification of Pazopanib in Renal Cell Carcinoma 465
data are yet available for pazopanib. The disease control
rate (DCR) in our report (n = 20; 29%) is slightly lower
than that reported in the literature, but it raised significantly
when considering the DCR reported in group 1 (44%). The
median PFS (not reported for group 1 and 17.9 months for
group 2 ? 3) was higher than that reported in other studies
[9, 10], but this might reflect the small sample considered
in the dose reduction cohort as well as the clinical man-
agement of side effects leading to longer treatment expo-
sure. Moreover, only subjects with clear cell histology and
good and intermediate prognosis treated with first-line
pazopanib were included in the study as per clinical prac-
tice in Italy. At both univariate and multivariate analysis,
dose reduction was associated with worse outcomes. These
results should be interpreted with great caution because of
methodological limits. Moreover, sampling variability was
high because of the low number of PFS events collected.
Imbalance of other confounders not considered in the
multivariate regression model could heavily bias effect
estimates. Different PFS assessments between groups and
time-varying PFS incidence rates could also bias effect
estimates. The lack of a preplanned hypothesis to test, the
retrospective nature of the data, the single institution
experience, and the small sample size must also be taken
into consideration in terms of the reliability and general-
izability of this study. In light of this variability and the
relationship between systemic exposure and clinical benefit
and toxicities, dose adjustments based on plasma concen-
trations may provide a method to optimize pazopanib
therapy by maintaining therapeutically effective blood
levels and minimizing AEs. To the best of our knowledge,
this is the first study to report outcomes for patients treated
with reduced-dose first-line pazopanib and may represent a
useful addition to the growing literature on TKIs in mRCC.
Fig. 1 Progression-free survival curves for groups 1 (G1), 2 (G2),
and 3 (G3)
Fig. 2 Progression-free survival curves for group 1 (G1) and groups
2 and 3 combined [G (2 ? 3)]
Table 4 Response rates
Characteristic Group 1 Group 2 Group 3 Total
Response rate
CR 3 (8.8) – – 3 (4)
PR 12 (35.3) 2 (10.5) 3 (18.8) 17 (25)
SD 11 (32.3) 7 (36.8) 4 (25) 22 (32)
PD 8 (23.5) 2 (10.5) 3 (18.8) 13 (19)
NA – 1 (5.2) –
Present status
Alive, on treatment 17 (50) 7 (37) 6 (38) 30 (43)
Drug discontinued due to death/progressive disease/toxicity/drug holiday 17 (50) 12 (63) 10 (62) 39 (57)
Data are presented as n (%)
CR complete response, NA not available, PD progressive disease, PR partial response, SD stable disease
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5 Conclusions
Our data may suggest that patients with mRCC receiving a
lower dose of first-line pazopanib might not have a
meaningful PFS advantage compared with those receiving
a standard dose. These results highlight that the optimal
management of treatment-related side effects may even-
tually lead to proper drug exposure.
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